Novartis

News

Daiichi Sankyo unit claims $182m in Novartis patent dispute

Novartis has settled a lawsuit brought by Daiichi Sankyo’s Plexxikon subsidiary, paying $180 million to resolve claims that its Tafinlar cancer drug infringed US patents h

News

Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH

Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuri

News

Merck pummelled as MS hope evobrutinib dies in phase 3

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th

News

Roche bounces back in PIK3 with inavolisib data

A few years ago, Roche abandoned the development of its lead PIK3CA-targeting drug taselisib on safety grounds, allowing rival Novartis to beat it to market, but now it ha

News

FDA launches wide probe into CAR-T therapy safety

The FDA has announced it will start an investigation into the safety of CAR-T therapies, after becoming concerned that they may be linked to the development of T-cell canc

News

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in

Daiichi Sankyo unit claims $182m in Novartis patent dispute

Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH

Merck pummelled as MS hope evobrutinib dies in phase 3

Roche bounces back in PIK3 with inavolisib data

FDA launches wide probe into CAR-T therapy safety

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks